Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn

Pulse Biosciences Inc ((PLSE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Pulse Biosciences’ latest earnings call struck a cautiously optimistic tone, with management highlighting strong clinical data, rapid procedure times and a fast‑growing patent estate that help de‑risk its core technology. Yet executives repeatedly acknowledged that revenue remains minimal, losses are substantial and commercialization is gated by future regulatory and reimbursement wins.

Clinical Feasibility Studies Showcase Promising Efficacy

European feasibility results for the nPulse electrophysiology catheter showed 100% procedural success at six months and 96% at one year for evaluable patients, alongside 90% freedom from atrial arrhythmia at 12 months on a Kaplan–Meier basis. Management stressed that routine ablation times of six to eight minutes could cut overall procedure duration by more than 50% versus legacy methods.

IDE Approvals Pave the Way for Pivotal Trials

The company secured IDE approvals for both the nPulse cardiac catheter and the NANOCLAMP AF surgical clamp, marking a key regulatory step. Pulse plans to complete enrollment for the roughly 155‑patient nPulse IDE and the 136‑patient NANOCLAMP AF pivotal study, spread across about 20 sites, during 2026.

Patent Portfolio Rapidly Expands Competitive Moat

Management highlighted aggressive intellectual‑property building, adding 67 issued and 77 pending patents in 2025, or roughly one new asset every 2.5 days. The company now holds 250 granted patents and about 180 pending applications, which it believes will reinforce barriers to entry around its nsPFA platform.

Vybrance Shows Early but Limited Commercial Uptick

Vybrance, the company’s aesthetic platform, delivered $264,000 in Q4 2025 revenue, which management itself labeled as nominal but encouraging. Sales rose from $86,000 in Q3, a roughly 207% sequential increase, driven by both system placements and disposable electrode usage in a deliberately constrained launch.

Partnerships and Regulatory Strategy Aim to Accelerate Adoption

Executives underscored efforts to forge mapping and broader EP ecosystem partnerships to support a future commercial rollout of nPulse. The company aims to submit for CE Mark approval of the nPulse catheter in the second half of 2026, with potential clearance in 2027, and to file a CE submission for the surgical clamp by year‑end 2026.

Cost Control Measures and Financing Flexibility

GAAP costs and expenses fell by $1.7 million year over year to $18.5 million in Q4 2025, an approximate 8% reduction that management framed as operational discipline. Pulse also put a $200 million shelf registration in place and believes current cash levels can fund major 2026 clinical milestones, giving it optionality on when to raise capital.

Tiny Revenue Base and Thin Gross Margins Highlight Early Stage

Total Q4 2025 revenue was just $264,000, while cost of product revenue nearly matched it at $260,000, leaving essentially no gross margin. The results underscore that Pulse remains squarely in the pre‑scale phase, with commercial economics still unproven and heavily dependent on future volume and pricing.

Operating Losses Persist Amid Trial and Launch Spending

GAAP net loss for Q4 2025 narrowed to $17.4 million from $19.4 million a year earlier, an improvement of about 10%. However, non‑GAAP net loss worsened to $12.2 million from $10.4 million as spending on clinical trials and the Vybrance launch increased, reflecting a conscious choice to invest ahead of revenue.

Cash Burn Rises as Development Efforts Ramp Up

Cash and equivalents fell to $80.7 million at year‑end 2025 from $118 million a year earlier, including a $14.5 million decline versus Q3. Operating cash use in Q4 climbed to $14.8 million, up from $9.1 million in the prior‑year quarter, signaling intensifying cash consumption tied to trials and early commercialization.

Non‑GAAP Expense Growth Points to Higher Near‑Term Needs

Non‑GAAP costs and expenses rose to $13.3 million in Q4 2025, an increase of about $2.0 million or 17.7% year over year. Management linked the higher run‑rate to expanded clinical activity and commercial groundwork, suggesting that near‑term cash requirements are likely to remain elevated.

Regulatory and Reimbursement Timelines Constrain Near‑Term Scale

Leadership emphasized that Vybrance remains in a deliberately limited launch until stronger data, reimbursement advances and additional clearances are secured. They cautioned that progress on reimbursement and expanded labeling is expected to take several quarters, which will cap revenue scalability in the near term.

Potential Need for Additional Capital or Strategic Partners

While the $200 million shelf registration offers funding flexibility, management acknowledged that more capital or strategic partnerships may be needed to support full commercialization. The company left the structure and timing of any future financing open, a key consideration for investors tracking dilution risk and balance‑sheet strength.

Guidance Emphasizes Clinical Milestones Over Near‑Term Revenue

Looking ahead, Pulse expects to initiate nPulse IDE enrollment within one to two months, complete enrollment for both the roughly 155‑patient catheter IDE and 136‑patient NANOCLAMP AF IDE in 2026, and advance thyroid studies toward larger cohorts and additional IDEs. Management is targeting CE submissions for both EP and surgical devices in 2026, while continuing a measured Vybrance rollout, disciplined spending and IP expansion, supported by existing cash and the shelf facility.

Pulse Biosciences’ call framed 2026 as a pivotal clinical year, with compelling early efficacy data and a deepening patent moat offset by thin revenue and rising cash burn. For investors, the story remains a high‑risk, high‑reward bet on successful trials, approvals and partnerships that could unlock a more meaningful commercial ramp later in the decade.